Tech Transfer eNews Blog

Bio-Techne licenses novel drug development tool from U of Dundee


By Jesse Schwartz
Published: August 3rd, 2022

Life sciences company Bio-Techne has signed an exclusive license agreement with the University of Dundee to commercialize a novel drug development tool.

Developed by Dundee researchers, the BromoTAG system enables scientists to determine which individual proteins show the greatest potential as targets for new therapeutic agents using an approach known as Targeted Protein Degradation (TPD).

Under the licensing agreement, Bio-Techne has exclusive rights to further develop and commercialize the BromoTAG system. The agreement also enables Bio-Techne to recruit postdoctoral researchers at the university’s Centre for Targeted Protein Degradation (CeTPD) to create new chemical tools for use by the biopharmaceutical research community.

“Bio-Techne has built a leading portfolio of tools and technologies to support scientists through every stage of their TPD research, and we are delighted to offer BromoTAG to researchers through this exclusive license,” says Will Geist, Bio-Techne’s Protein Sciences Segment President. “We have a long-standing relationship with the University of Dundee to commercialize exciting and useful technologies and look forward to expanding this relationship through our support of post-doctoral research.”

Alessio Ciulli, professor at the University of Dundee and pioneer in the TPD field, comments, “We will jointly work to develop the next-generation BromoTAG for a variety of applications. The licensing deal deepens the relationship between the University and Bio-Techne. These developments cement the importance of our research to the field of targeted protein degradation.”

Source: Cision

Posted under: Tech Transfer e-News